This clinical trial is focused on studying a type of blood cancer called Acute Myeloid Leukemia (AML), which affects children and young adults. The study is investigating a treatment using a medication called Quizartinib, also known by its code name AC220. Quizartinib is a type of drug known as a Class III receptor tyrosine kinase inhibitor, which is designed to target specific mutations in cancer cells. The trial aims to evaluate the safety and effectiveness of Quizartinib when used in combination with chemotherapy and as a standalone treatment.

The purpose of the study is to determine the best dose of Quizartinib for different age groups and to assess how well it works in achieving remission, which means the cancer is no longer detectable. The study will also look at the safety of the treatment and how the body processes the medication. Participants will receive Quizartinib along with chemotherapy for up to two cycles, with the option for additional treatment if needed. After this, Quizartinib may be given alone for up to twelve cycles to see if it helps keep the cancer from returning.

This trial is specifically for patients with a mutation called FLT3-ITD, which is found in some cases of AML. The study will monitor how well the treatment works in reducing cancer cells and how long the remission lasts. It will also track any side effects experienced by participants. The goal is to find a safe and effective treatment option for young patients with this type of leukemia.